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Background: Immunological quiescence in the central nervous system (CNS) is a potential barrier to immune
mediated anti-tumor response. One suppressive mechanism results from the interaction of parenchyma-derived
CD200 and its receptor on myeloid cells. We suggest that CD200/CD200R interactions on myeloid cells expand the
myeloid-derived suppressor cell (MDSC) population and that blocking tumor-derived CD200 will enhance the
efficacy of immunotherapy.
Methods: CD200 mRNA expression levels in human brain tumor tissue samples were measured by microarray. The
amount of circulating CD200 protein in the sera of patients with brain tumors was determined by ELISA and, when
corresponding peripheral blood samples were available, was correlated quantitatively with MDSCs. CD200-derived
peptides were used as competitive inhibitors in a mouse model of glioblastoma immunotherapy.
Results: CD200 mRNA levels were measured in human brain tumors, with different expression levels being noted
among the sub groups of glioblastoma, medulloblastoma and ependymoma. Serum CD200 concentrations were
highest in patients with glioblastoma and correlated significantly with MDSC expansion. Similarly, in vitro studies
determined that GL261 cells significantly expanded a MDSC population. Interestingly, a CD200R antagonist inhibited
the expansion of murine MDSCs in vitro and in vivo. Moreover, inclusion of CD200R antagonist peptide in glioma
tumor lysate-derived vaccines slowed tumor growth and significantly enhanced survival.
Conclusion: These data suggest that CNS-derived tumors can evade immune surveillance by engaging CD200.
Because of the homology between mouse and human CD200, our data also suggest that blockade of CD200
binding to its receptor will enhance the efficacy of immune mediated anti-tumor strategies for brain tumors.
Keywords: Checkpoint inhibitors, Immunotherapy, Immune suppression, Brain tumorsBackground
Immune suppression occurs naturally via multiple mecha-
nisms [1,2], serving an important role by resolving inflam-
mation and returning the tissue microenvironment to
homeostasis. There is clear evidence now that many tu-
mors employ various immunosuppressive mechanisms to
evade immune surveillance and to promote tumorigenesis
[2,3]. The two most studied immune inhibitory receptors* Correspondence: olin0012@umn.edu
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unless otherwise stated.are cytotoxic T lymphocyte antigen 4 and programmed cell
death protein 1, both of which are expressed on effector
T-cells [4,5]. Monoclonal antibodies specific for these re-
ceptors extend survival in subsets of cancer patients, pre-
sumably by blocking ligand binding to these receptors and
preventing inhibition of T-cell effector functions [5]. These
striking clinical results suggest that brain tumor immuno-
therapy would benefit from the identification and subse-
quent blockade of immune inhibitory pathways in the
central nervous system.
An immune inhibitory ligand/receptor pair that main-
tains immune quiescence in the CNS is CD200/CD200Rl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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protein with a broad tissue distribution. In the CNS,
CD200 is expressed predominantly by neurons [6,7],
down-modulating the activation state of perivascular mac-
rophages and microglia through CD200R [8]. Mice
express multiple CD200R isoforms that exhibit tissue-
restricted expression and heterogeneity of function [9-12].
Recent studies have reported the expression of CD200R1
on microglia, macrophages, dendritic cells and a subpopu-
lation of T cells. Ligation with its ligand, CD200, negatively
regulates immune responses through multiple mecha-
nisms [13-15] including the activation of CD200R on
MDSCs promoting tumorigenesis [14].
Results
CD200 is overexpressed by many brain tumors
To gain a better understanding of the role of CD200 in
CNS tumors, we first examined CD200 mRNA expression
on a variety of tissues. The data demonstrate an overall
statistically significant increase in mRNA transcript levels
in normal brain compared to non-brain tissues (p = 0.001)
(Additional file 1: Figure S1A). In addition, we observed
increased CD200 expression throughout the brain with
the exception of the choroid plexus, which was statisticallyFigure 1 Brain tumors express CD200. A. Western analysis of CD200 on
Meningioma; (MEN), Ependymoma; EPN, Oligodendroglioma; ODG and Pilocyt
(n = 30) and meningiomas; (MEN, n = 14) were compared to Glioblastoma Mul
Astrocytoma; (PA, n = 17), Anaplastic Oligoastrocytoma; (AO, n = 3), Oligodendr
Medulloblastoma; (MED, n = 30), Ependymoma; (EPD, n = 45) and Craniopharyn
Glioblastoma Multiforme subsets compared to Proliferative; Prolif, Mesenchyma
were compared between Ependymoma subsets Posterior Fossa A (PFA), Poste
Hedgehog positive (SHH+) compared to group 3 (cMYC+) and group 4 (Sonic
E. Serum concentrations of soluble CD200 were analyzed from patients bearing
Ependymoma; EPD, Medulloblastoma; MED, Meningioma; MEN and healthy do
glioblastoma multiforme was correlated to expansion of lineage negative MDS
by one-way ANOVA, post hoc analysis by Dunn’s multiple comparison test, *plower than the rest of the brain combined (p = 0.005). Post
hoc analysis determined a significantly increased expres-
sion in breast, kidney, lung (p < 0.001) and pancreas (p <
0.0001). Thymus failed to reach statistical significance. In
addition, post analysis revealed a statistically significant dif-
ference between choroid plexus and frontal and temporal
lobes (p < 0.001 and p < 0.05 respectively). Cerebellum,
hippocampus, lumbar spinal cord, medulla, midbrain, pons
and occipital lobe failed to reach statistical significance
(Additional file 1: Figure S1B).
Given its high expression on normal CNS tissue, we
investigated the expression of CD200 on multiple cen-
tral nervous system tumors. We found CD200 protein
expressed on a variety of human brain tumor tissue
samples by western analysis: anaplastic oligoastrocy-
toma (n = 1), GBM (n = 3), meningioma (n = 1), ependy-
moma (n = 2), oligodendrogliomas (n = 1) and pilocytic
astrocytoma (n = 1)(Figure 1A). Given these initial find-
ings, we next compared CD200 mRNA levels in a larger
cohort of brain tumors relative to normal brain and
meningioma (MEN), an extra-axial tumor arising in the
lining of the CNS, not a true brain tumor. We observed
a statistically lower expression (p < 0.0001) on meningi-
oma (MEN), glioblastoma multiforme (GBM) andAnaplastic oligoastrocytoma; AO, Glioblastoma Multiforme; GBM,
ic Astrocytoma; PA. B. mRNA CD200 expression levels in normal brain;
tiforme; (GBM, n = 31), Anaplastic Astrocytoma; (AA, n = 5), Pilocytic
ogliomas; ODG, n = 4), Primitive Neuroectodermal; (PNET, n = 13),
gioma; (CRP, n = 11). C. mRNA CD200 expression levels on Proneural; PRO
l; Mes and Promesenchymal; Promes. D. CD200 mRNA expression levels
rior Fossa B (PFB), Supratentorial (ST) and Medulloblastoma subsets Sonic
Hedgehog negative/cMYC negative (SHH-cMYC-)) subsets. In addition,
Anaplastic Oligoastrocytoma; AO, Anaplastic Astrocytoma; AA,
nors; HD. F. Serum concentration of soluble CD200 from patients bearing
C population. Means are indicated, statistical significance was determined
< 0.05, **p < 0.001. R2 was determined using linear regression.
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ingiomas were significantly lower (p < 0.0001) than all
other tumors.
Interestingly, further analysis of GBMs revealed an in-
creased expression of CD200 in the proneural subtype
compared to proliferative (p < 0.001), mesenchymal (p <
0.0001) and promesenchymal tumors subsets (p < 0.0001)
(Figure 1C). We chose to look at promesenchymal gene
expression based on studies by Nelson, et al. and Prins,
et al. [16-18]. They reported a subset that featured both
proliferative (classical) and mesenchymal groups, which
was subsequently named promesenchymal. This was pub-
lished in BMC Medical Genomics in 2008 and corrobo-
rated by other groups.
In addition to gliomas, we also observed a statistically
significant increase in the supratentorial ependymoma
subset compared to posterior fossa group A and poster-
ior fossa group B (p = 0.0001 and p = 0.001 respectively).
In addition, CD200 mRNA levels were significantly ele-
vated in the group 4 (sonic hedgehog/cMYC negative)
medulloblastoma subset compared to sonic hedgehog
positive (SHH+) and group 3 (cMYC+) subsets (p = 0.001
and p = 0.001 respectively) (Figure 1D) [19,20].
CD200 is expressed on multiple tumor types [21,22].
Wong, et al. reported CD200 on cells from chronic
lymphocytic leukemia patients [23], however, they went
on to state that the soluble form of CD200 (sCD200) in
the sera of patients is what correlated with poor patient
outcomes [23]. Therefore, we analyzed sera from brain
tumor patients for sCD200 levels. We observed a signifi-
cant difference in sCD200 levels between patients with
various brain tumor types by ANOVA (p = 0.001). Post
analysis revealed a significant increase in sCD200 in pa-
tients with glioblastoma multiforme GBM compared to
patients with ependymoma (p < 0.001) (Figure 1E). Three
patients in the GBM group with the highest concen-
trations of sCD200 had aggressive recurrent disease.
Furthermore, the highest concentration in the medullo-
blastoma group was from a patient in our clinical trial
[24] who rapidly went off trial due to tumor progression.
Interestingly, an ependymoma patient in the same trial
had a statistically significant increase of sCD200 (p <
0.01 between weeks 4 and 12) as she went off trial due
to recurrence (Additional file 2: Figure S2A). Together,
our data support the reported correlation between ele-
vated sCD200 and poor prognosis.
One potential mechanism by which CD200 induces an
immune suppressive environment is through the expan-
sion of MDSCs [10]. Therefore, we sought to correlate
sCD200 in patients’ sera with the percentage of periph-
eral blood lineage negative MDSCs. The patients were
all participants in a recent clinical trial designed to test
the safety of our allogeneic vaccine [24] and included
those with ependymoma (n = 1) and GBM (n = 3);correlations between sCD200 in the sera and MDSC fre-
quencies were made just prior to vaccination, and at 4, 8,
and 12 weeks post-vaccination [24]. There were significant
correlations between sCD200 and expansion of MDSCs in
the GBM patients (Figure 1F; R2 = 0.99) and ependymoma
patient (Additional file 2: Figure S2 B; R2 = 0.97). These
data suggest a direct correlation between sCD200 and
MDSC expansion.
CD200 pathway blockade reduces immune suppression
induced by sCD200
Based on the work of Gorczynski, et al. [9], we synthesized
a CD200R antagonist peptide (A26059) to determine the
ability of tumor secreted CD200 to block the expansion
of MDSCs. The addition of GL261 glioma tumor cells
induced a significant expansion of CD11b+Gr1+ MDSC
(p < 0.01) and suppressed the ability of purified OT-I
CD8 T-cells to respond to OVA (SIINFEKL) stimula-
tion (p < 0.01) (Figure 2A). The addition of the CD200R
antagonist blocked both the expansion of MDSCs as
well as the production of IFN-γ (p < 0.01 and p < 0.01
respectively) (Figure 2A).
To validate that MDSC expansion is due to CD200, naïve
splenocytes were pulsed with purified recombinant CD200
protein with and without the CD200R antagonist (A26059).
These experiments show that CD200 alone significantly
expanded the MDSC population (p < 0.01). Pre-incubating
cells with the CD200R antagonist significantly blocked
CD200-induced MDSC expansion (p < 0.01) (Figure 2B),
and blocked arginase-I secretion (p < 0.01) (Figure 2C).
There was a significant increase of MDSCs between treat-
ment groups using the antagonist compared to a control
antagonist (p < 0.001) (Additional file 3: Figure S3A).
CD200R antagonist blocks tumor induced suppression
resulting in an extension in survival glioma bearing mice
We previously reported that vaccinating GL261 glioma
bearing mice near the sentinel (cervical) lymph nodes
failed to elicit an effective tumoricidal response [25].
In addition, we demonstrated, as described above, that
glioma cells have the ability to enhance a MDSC popula-
tion (Figure 2A). Therefore, we investigated the ability
of our CD200R antagonist to block/reverse the in vivo
suppressive effects of sCD200. Tumor bearing and non-
tumor bearing mice were vaccinated in the back of
the neck with OVA + Poly:ICLC to induce an antigen
specific cellular immune response. The data presented in
Figures 3 A and B show that the percentage of OVA spe-
cific SIINFEKL binding CD8+ T-cells (p < 0.01) as well
as the ability to induce TNFα and IFNγ are significantly
suppressed (p < 0.001 and p < 0.01 respectively) in OVA
primed GL261 bearing mice (white bars) compared
to non-tumor bearing mice (black bars). To investigate
the potential role of CD200 in GL261 glioma induced
Figure 2 CD200R antagonist blocks MDSC expansion and
tumor suppressive effects. A. Murine glioma GL261 was incubated
with naïve splenocytes in a trans-well plate +/- CD200R antagonist and
analyzed for MDSC expansion and cytokine production. B. Naïve
splenocytes were pulsed with purified CD200 +/- CD200R antagonist
and analyzed for MDSC expansion and arginase-I production. Error bars
are ± SEM, statistical significance was determined using an unpaired
T-test, *p < 0.05, **p < 0.001.
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onist 6059 into our vaccine inoculum. Tumor-bearing
mice treated with the CD200 antagonist one day prior to
and concurrently with OVA vaccine had increased num-
bers of SIINFEKL-specific CD8 T-cells compared to mice
vaccinated without the antagonist (p < 0.01) (Figure 3A).
Moreover, lymphocytes isolated from the cervical lymph
nodes of mice vaccinated with the addition of the CD200R
antagonist had significantly enhanced TNFα and IFNγ
production (p < 0.01 and p < 0.001, respectively)(Figure 3B).
These experiments suggest that CD200 plays a role in sup-
pressing the immune responses in GL261 tumor bearing
mice.
We next investigated whether the CD200R antagonist
could enhance survival in our GL261 mouse model. Mice
were given the CD200R antagonist 6059 one-day prior to
and concomitantly with vaccination. We observed a statis-
tically significant inhibition of tumor growth in mice vac-
cinated with antagonist compared to mice vaccinated withtumor lysates alone (p < 0.001) and mice that received
saline only as a control (Figure 3C). The addition of the
CD200R antagonist with the vaccine significantly slowed
tumor growth (p < 0.01), resulting in enhanced survival
benefit (p < 0.01) compared to other treatment groups
(Figure 3C and D).Modified CD200R antagonists enhance survival in glioma
and breast carcinoma models
Gorczynski reported that multiple regions of the CD200
act as antagonist, blocking the suppressive effects of
CD200 [9]. Ongoing investigations of another CD200R
antagonist demonstrates even greater survival (p < 0.001)
(Figure 4A) compared to the 6059 in our GL261 glioma
model. Subsequent experiments demonstrated that de-
creased tumor growth is due to the use of our new an-
tagonist (A26059). Using control peptide failed to inhibit
tumor growth (Additional file 3: Figure S3 B). However,
differences between mice given a CD200R antagonist
and the control antagonist failed to reach statistical
significants.
To test if our antagonist was efficacious in a non-CNS
tumor, we tested multiple CD200 antagonists on our
breast carcinoma model. CD200R antagonists 4004,
4013 and 6059 showed enhanced survival benefit in an
EMT6 breast carcinoma model (Figure 4B). Interest-
ingly, CD200R antagonist 4013 and 4004 failed to confer
survival in our glioma model (data not shown). All mice
were tumor free by day 100 when they were challenged
with 1 × 106 EMT6 cells. Regardless of the CD200R an-
tagonist used, all mice rejected challenge without further
vaccinations. These experiments demonstrate the ability
of small molecule peptides to mitigate the negative sig-
nals of the CD200/CD200R interaction.Discussion
Because of the myriad of ways tumors induce immunosup-
pression, it is unlikely that any monotherapy will be com-
pletely effective. Therapy using a combination of vaccine,
adoptive cell therapy, checkpoint inhibitors or other
immune-stimulating therapies will likely have better re-
sults. Several immunotherapeutic approaches, such as
agents targeting the known immune checkpoints, have
been developed and are under evaluation as cancer inter-
ventions [26-28]. We found increased expression of CD200
mRNA in multiple human brain tumors as well as in-
creased soluble CD200 (sCD200) concentrations in the
sera of patients as their tumors progressed. A CD200R
antagonist peptide mitigated glioma-induced immune
suppression in mice. The combination of this peptide and
a glioma-derived vaccine significantly extended survival in
glioma-bearing mice. Our data suggest that gliomas have
co-opted CD200-mediated immune suppression to persist,
Figure 3 CD200R antagonist blocks CD200 induced immune suppression enhancing survival. A and B. Tumor bearing mice were
vaccinated with OVA + Poly:ICLC +/- antagonist then analyzed for OVA-specific T cells and cytokine production following in vitro restimulation
with OVA. Tumor bearing mice were vaccinated with saline (n = 10), tumor lysate + CpG (n = 10) or tumor lysate + CpG + antagonist 6059 (n = 10).
C. Mice were imaged weekly for tumor growth and (D) followed for survival. Error bars are ± SEM, *p < 0.05, **p < 0.001 was determined by
one-way ANOVA, post hoc analysis by Dunn’s multiple comparison test, log-rank analysis was used for survival. Error bars are ± SEM, statistical
significance was determined using an unpaired T-test, *p < 0.05, ** p < 0.001.
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is a viable strategy for glioma therapy.
We believe that the soluble form of CD200 (sCD200) de-
rived from tumors is carried to the cervical lymph nodes
through the cerebral spinal fluid, inducing negative signals
by placing severe limitations on the ability of the immune
system to mount a tumoricidal response following vaccin-
ation. In contrast to non-CNS tissues, we detected high
expression levels of CD200 throughout the brain with the
exception of the choroid plexus (Additional file 1: Figure
S1 A & B). It was not surprising that brain tumors, due to
the origin of the cells, had high expression levels of CD200
(Figure 1B). However, compared to most CNS tumors,
GBMs had lower expression of CD200. Therefore, we in-
vestigated data derived from the TCGA database. Expres-
sion of CD200 was down regulated in 2% of the RNAseq
data (3 out of 153 tumors), 6% of the U133 Microarray
data (33 out of 528 tumors) and 7% of the Agilent Micro-
array data (36 out of 500 tumors). Overall, altered expres-
sion of CD200 is detected in 6% of ~1200 GBM tumors.
Altered CD200 expression in GBM tumors from the
TCGA database (Grade IV) did not correlate with survival
or relapse (Log-rank p-value not significant). Likewise,altered expression of CD200 in GBM tumors from the
REMBRANDT database (grades II, III, IV) did not correl-
ate with survival.
Interestingly, none of the altered CD200 samples from
RNAseq or U133 Microarray data co-occurred with IDH1
mutations (~5% of GBM tumors), however, no significant
association was calculated (in this case, by mutual exclu-
sion). In the Agilent Microarray CD200 up-regulated sam-
ples, only one of the samples co-occurred with an IDH1
mutation and, again, no significant association was calcu-
lated (co-occurrence or mutual exclusivity). It is important
to note these statistical results may be due to small sample
size but the non-overlapping trend of altered CD200 ex-
pression and IDH1 mutations is interesting. No IDH2 mu-
tations were detected in any of the GBM tumors analyzed
for mRNA expression.
We have found that CD200 expression varies within
different tumor types, and that specific tumor subsets
also have varying expression levels of CD200. We saw a
significant increase in CD200 expression levels in the
proneural subset of GBM compared to mesenchymal
GBM. This is interesting because the proneural subset is
associated with minimal immune cell infiltrate, limiting
Figure 4 Modified CD200 antagonists enhance survival. A. EMT6 tumor bearing mice were vaccinated with tumor lysate, CpG +/- CD200
antagonist 4004, 4013 or 6059. B. New CD200R antagonist A12-6059 enhances survival. Log-rank analysis was used for survival.
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with the proneural subset of GBM have a more favorable
prognosis than the mesenchymal subset, which is associ-
ated with high cell infiltrates. This may be due to the low
accumulation of MDSCs or M2 type macrophages that
permit tumor growth [29]. The same trend may be true
for ependymoma and medulloblastoma subsets, posterior
fossa A and group 3 (cMYC+) subgroups, respectively,
which are more aggressive, have low CD200 expression
and exhibit high immune infiltrates [19,30,31].
CD200 negatively regulates immune function through
interactions with the CD200 receptor [10]. CD200/
CD200R interactions result in the expansion of sup-
pressive cell populations such as MDSC [32]. In our
studies, we observed a positive correlation between soluble
CD200 concentration and lineage negative MDSC expan-
sion in both our GBM and ependymoma immunotherapy
patients as they progressed and went off trial (Figure 1F
and Additional file 2: Figure S2 B respectively). These
studies demonstrate a direct correlation between sCD200
and the expansion of the suppressive cells. However, werecognize that this study has a low number of patients.
Although studies are ongoing to support our observations
in humans, we have demonstrated that sCD200 induces
expansion of MDSCs in our murine glioblastoma model.
To overcome the immunosuppressive nature of tumors,
agents targeting the known immune checkpoints (check-
point inhibitors) have been developed and are under evalu-
ation as cancer interventions [26-28]. These inhibitors, in
combination with current immunotherapy regimens, re-
markably enhance the efficacy of anti-tumor immunother-
apy. Checkpoint inhibitors block the interactions between
ligands and their receptors. Two humanized antibodies,
ipilimumab and nivolumab [33], have been developed as
checkpoint inhibitors to block negative signals to T cells.
In addition, anti-CD200 demonstrated efficacy in a B-cell
chronic lymphocytic leukemia [34] that led to the use in a
clinical trial (clinicaltrials.gov identifier NCT00648739).
Our data demonstrate that CD200R antagonist peptides
reverse/block GL261-derived immune suppression within
tumor-draining lymph nodes. This reversal is striking
given the aggressiveness of GL261 and the many ways it
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is a central driver of glioma-mediated immune suppression.
Conclusion
Our current hypothesis is that the CD200R antagonists
bind to CD200R on local dendritic cells, protecting them
from the suppressive effects of soluble CD200 upon
entry into the draining lymph nodes. This hypothesis
was determined from preliminary data showing that vac-
cinating mice with the CD200R antagonist significantly
enhanced the expansion of a SIINFEKL/CD8 T cell
population (Figure 3A). However, early studies revealed
that mice had to be pre-vaccinated with the antagonist
prior to tumor lysate vaccination in order to achieve a
survival benefit. We speculate that this was due to the
presence of sCD200 within our tumor lysates competing
for the CD200R on dendritic cells. Ongoing investiga-
tions are in progress to verify this. The data presented
here are significant and are a part of a more comprehen-
sive study to further understand the effects of CD200 in
cancer, specifically how CD200 expands a MDSC popu-
lation. Mechanistic studies are ongoing and not within
the scope of this manuscript. Nevertheless, we demon-
strate the potential importance of CD200 in tumor
immunotherapy and the use of antagonist peptides
as effective agents to block the suppressive effects of
sCD200. Our data suggest these antagonist peptides will
be useful to enhance immunotherapy not only for gli-
oma, but for breast carcinoma as well. We anticipate
that our results will lead to the development of novel in-
hibitors of the CD200R pathway that can be used as im-
munotherapy adjuncts to mitigate the suppressive tumor
environment in a variety of human cancers.
Methods
Patient sample collection
Patients undergoing care for brain tumors were identi-
fied and consented prior to surgical biopsy and/or resec-
tion. Patients and/or their legal representative were
consented according to institutional guidelines. Patients
were treated at one of four participating institutions: the
University of Minnesota, the University of Pittsburgh,
the University of Colorado and UCLA. Patient tissue
and blood samples were collected and stored for analysis
at the University of Minnesota.
Western blot analysis
Tissues were minced and sonicated in RIPA lysis buffer
containing protease and phosphatase inhibitors (Pierce).
Protein concentrations were determined using the
bicinchoninic acid colorimetric method (Pierce). Tumor
lysates were diluted in reducing sample buffer (Novex)
and 50 μg were loaded per lane on a 4% to 12% SDS-
PAGE gel (Nu-Page) and run at 160 volts (0.8 volt hours).Gels were then transferred to nitrocellulose at 7 volts
(BioRad), blocked using 5% non-fat dry milk/0.05 mM tris
buffered saline with 0.05% tween-20 for 1 hr, incubated at
1:1000 in anti-OX2, 200 μg/ml (Santa Cruz) in blocking
buffer for 1 hr, and washed six times over 1 hr in TBS/
Tween-20. Blots were then incubated at 1:10,000 with
anti-goat, 500 μg/0.5 ml IgG HRP (Jackson ImmunoRe-
search) in blocking buffer for 1 hour and washed six times
over 1 hour in TBS/Tween-20. Nitrocellulose was incu-
bated in ECL Plus chemiluminescent substrate (GE) for
1 minute and exposed to HyBlot CL Autoradiography film
(Denville Scientific) for 30 seconds.
Microarray analysis
Data for Figure 1B and D and Additional file 2: Figure S2,
transcriptomic microarray profiles of tumor and normal
brain tissue samples were generated using Affymetrix HG-
U133 Plus 2 GeneChip microarrays (Affymetrix) as previ-
ously described [35]. RNA was isolated from specimens
using RNeasy or DNA/RNA AllPrep kit (Qiagen) accord-
ing to manufacturer’s instructions. Tumor specimens from
which both RNA and DNA were isolated were determined
by histology to contain ≥70% tumor cells and thus had
minimal normal tissue contamination. RNA quality was
verified using the Nano Assay Protocol for the 2100 Bioa-
nalyzer (Agilent) (RNA integrity number ≥ 8). RNA was
amplified, biotin-labeled, and hybridized to Affymetrix
HGU133 Plus 2 GeneChips according to manufacturer’s
instructions. Analysis of transcriptomic microarray data
was performed using Bioconductor functions written in
the R programming language (http://www.bioconductor.
org). Microarray data CEL files were background corrected
and normalized using the guanine cytosine robust Multiar-
ray Average (gcRMA) algorithm, resulting in log2 expres-
sion values. Normalized hybridization intensity values for
CD200 were obtained from this dataset and averaged for
each type and molecular subtype of pediatric brain tumor.
For Figure 1C, total RNA was purified from fresh fro-
zen tumor samples previously collected as part of an
IRB-approved research protocol using the RNeasy mini
kit (Qiagen). cRNA was generated, quantified and hy-
bridized to U133 Plus 2.0 arrays at the UCLA DNA
Microarray Facility using standard Affymetrix protocols.
CEL files were normalized using GeneSpring GX 11.5.1
software (Agilent Technologies). To evaluate the base-
line expression of CD200 in heterogeneous human brain
tumor tissues, we analyzed the relative expression of
CD200 using microarray gene expression profiling in
over 300 human brain tumor samples and segregated
the data by known gene expression signatures. The rela-
tive expression of CD200 was normalized and tested.
CD200 expression was then plotted together with overall
survival using the Probeset Analyzer tool developed at
UCLA (http://probesetanalyzer.com).
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GL261 glioma tumors were implanted into female
C57BL/6 mice (6–8 wk old) (Jackson Laboratory) and
maintained in a pathogen-free facility according to the
guidelines of the University of Minnesota Animal Care
and Use Committee. The GL261 orthotopic transplant
model was established in C57BL/6 (B6) mice by inocula-
tion with 15,000 GL261-Luc+ cells in 1 μl of saline [36].
Tumors were implanted stereotactically into the right
striatum; coordinates were 2.5 mm lateral, 0.5 mm an-
terior of bregma, and 3 mm deep from the cortical sur-
face of the brain [25]. Tumor burden was determined by
bioluminescent imaging. Light emitted from the tumors
was quantified using Living Image software (Xenogen)
and expressed as photons per second per centimeter
squared per steradian (p/s/cm2/sr). GL261 cells for
tumor lysate vaccines were cultured in neural stem cell
media consisting of DMEM/F12 (1:1) with L-glutamine,
sodium bicarbonate, penicillin/streptomycin (100 U/ml),
B27 and N2 supplements (Life Technologies), and
0.1 mg/ml Normocin (Invivogen). Cultures were main-
tained at 5% O2 and supplemented with 20 ng/ml EGF
and FGF semiweekly (R&D Systems, Minneapolis, MN).
The breast carcinoma EMT6 model was established
in BALB/c mice by injection of 1 × 106 EMT6 cells in
50 ml of PBS into the left superior mammary fat pad as
described [37]. Mice were euthanized when tumors
reached 1000 mm3. Mice were challenged with 1 × 106
EMT6 cells in 50 ml of PBS into the left superior mam-
mary fat pad. Tumor cells used to establish both models
were cultured in DMEM containing 10% FBS, penicillin/
streptomycin (100 U/ml), and 0.1 mg/ml Normocin
(Invivogen) in atmospheric oxygen.
CD200R antagonists
Based on a report from Gorczynski [9], we synthesized
the CD200R antagonists 6059 (NTIGDGGCY), 4013
(LFNTFGSQKVSGT) and 4004 (TASLRCSLKTSQE) and
for activity (Thermo Fisher). We decided to modify the
CD200R antagonist now A26059 (STVHEILCKLSLEGD
(dPEG4)NTIGDGGAY) and its irrelevant peptide control
was derived by Thermo Scientific (STVHEILCKLSLEGD
(dPEG4)LESHLIKVS).
Vaccine preparation and injection
Tumor lysates were prepared by dissociating tumor cells
with non-enzymatic dissociation solution (Sigma). Cells
were then washed 3 times with PBS, re-suspended in
500 μL PBS, and frozen overnight at -80°C. Cells were
then lysed by five freeze/thaw cycles of freezing in liquid
nitrogen and thawing in a 55°C water bath. Cell debris
was pelleted by centrifugation at 14,000 RCF, and the pro-
tein concentration of the supernatant was determined
using a Bradford assay. Lysates were stored at -80°C untiluse. Each vaccine was prepared on the day of vaccination
and consisted of 65 μg of protein tumor lysate and 10 μg
Poly:ICLC (a kind gift Dr. Salazar Dr, Oncovir, Inc.), with
or without 50 μg of the 6059 peptide antagonist, in a final
volume of 100 μL injected intradermally in the back of the
neck. For survival studies, vaccines were administered
weekly starting three days post-tumor implantation for a
total of 6 doses. For T cell priming experiments, animals
were vaccinated intradermally on four consecutive days
with 100 μg Ovalbumin (OVA) and 10 μg Poly:ICLC, and
once more on day eleven [25].
Flow cytometry
Anti-mouse CD8α-Pacific Blue (clone 53-6.7) was pur-
chased from eBioscience. A SIINFEKL/Kb dextramer–PE
was used for detection of SIINFEKL/Kb-binding CD8
T-cells (Immunodex). For whole blood staining, 50 μL of
blood was obtained via retro-orbital bleed and placed in
100 μL in heparin and PBS. 5 μL of SIINFEKL/Kb dextra-
mer was added to the blood and incubated at room
temperature for 10 min. Then 0.5 μg of antibody was
added and incubated for an additional 20 min. Red blood
cells were lysed by adding 1 mL of 1:10 dilution lysis buffer
(BD Pharmigen), incubated for 10 min, washed twice ana-
lysis by flow cytometry. Data analysis was performed using
FlowJo software. In our human experiments, peripheral
blood mononuclear cells and whole blood for serum were
isolated from patients at vaccination and on weeks 4, 8, 12,
and 24 post vaccination in a recent clinical trial [24]. A
100 μl sample of whole blood was immediately analyzed
for percentage of MDSCs ((Lineage-FITC (CD3, CD14,
CD16, CD19, CD20, CD56) CD33-APC, HLA-DR-PerCp))
by flow cytometry. Sera CD200 levels were determined by
ELISA as instructed by manufacture (Sino Biological Inc,
China).
Cytokine detection
Lymph nodes were homogenized in RPMI media con-
taining 10% FBS, penicillin/streptomycin (100 U/ml),
and 0.1 mg/ml Normocin (Invivogen). Cells were filtered
using a 70-micron filter, centrifuged and resuspended at
a concentration of 500,000 cells/well in triplicate, stimu-
lated with 10 μg of OVA and incubated for 48 hrs. Fifty
microliters of supernatant was analyzed for IFN-γ using
a flow cytometric bead array according to the manufac-
turer’s protocol (BD Biosciences).
MDSC detection and analysis
Spleens were harvested and homogenized in RPMI media
containing 10% FBS, penicillin/streptomycin (100 U/ml),
and 0.1 mg/ml Normocin (Invivogen). Cells were then
filtered using a 70-micron filter, centrifuged, and re-
suspended in 5 ml of Ammonium-Chloride-Potassium
buffer and incubated for 5 minutes at room temperature
Moertel et al. Journal for ImmunoTherapy of Cancer  (  Page 9 of 10to lyse RBCs. Following lysis, cells were washed and plated
into 96 well plates at a concentration of 500,000 cells/well
in triplicate. Following 24 h incubation, CD200R antagon-
ist peptide A26059 was added to the appropriate wells,
incubated for 20 min prior to adding 5 μg of purified
CD200 protein (Sino Biological, China) and incubated for
a further 72 hrs, harvested and analyzed for anti-CD11b
and anti-Ly6c population using an LSR II flow cytometer.
To determine the level of MDSC expansion when sple-
nocytes were exposed to tumor cells, splenocytes were
also harvested and purified as described above; 300,000
splenocytes were plated in the bottom of 24 well trans-
well plates containing a 0.4-micron filter. Following
24 hr incubation, 30,000 GL261 cells were plated on the
transwell insert with and without the CD200R antagonist
A26059. Total volume was 700 μl/well so that the insert
was submerged in the media within the wells. Cells were
incubated for 5 days, harvested, and stained with CD11b
and GR-1 to determine MDSC levels. In another set
of wells, OVA was added to the wells 24 hours after the
splenocytes were plated. Following another 72 hr incu-
bation, 3x105 purified CD8 T-cells isolated from an OT-
I mouse and were added to the wells and incubated for
an additional 72 hrs. Supernatant was harvested and
used to determine IFN-γ concentration levels by bead
array (BD Biosciences).Statistical analysis
Statistical comparisons were made by one-way ANOVA
(Kruskal-Wallis test) with post hoc analysis by Dunn’s
multiple comparison tests to compare selected groups.
Correlations were determined by linear regression with a
95% confidence level plotting the averages of sCD200 con-
centration in patient’s sera vs. MDSC percentages over
time as the patients went off a clinical trial. Differences in
animal survival were evaluated by log-rank test. All tests
were done with Prism 5.0d software (Graph Pad Software,
Inc). P values <0.05 were considered significant.Additional files
Additional file 1: Figure S1. Variable tissue expression of CD200. (A)
mRNA expression levels of CD200 from indicated tissues were analyzed
by microarray. (B) mRNA expression levels of CD200 from different
regions of normal brains were analyzed by microarray. Means are
indicated, statistical significance was determined by one-way ANOVA,
post hoc analysis by Dunn’s multiple comparison test, *p < 0.05,
**p < 0.001, ***p < 0.0001.
Additional file 2: Figure S2. Soluble CD200 concentration increases
with tumor reoccurrence. (A) Sera CD200 concentration from an
ependymoma patient was monitored overtime throughout a recent clinical
trial and (B) compared to patients lineage negative levels as she progressed
and went off trial. Means are indicated, statistical significance was determined
by one-way ANOVA, post hoc analysis by Dunn’s multiple comparison test,
*p < 0.05. R2 was determined using linear regression.Additional file 3: Figure S3. Control CD200R antagonist fails to block
the suppressive effects of CD200. A. Naïve splenocytes were pulsed with
purified CD200 +/- CD200R antagonist or CD200 +/- control antagonist and
analyzed for MDSC expansion and arginase-I production. B Tumor bearing
mice were vaccinated with saline (n = 5), tumor lysate + CpG (n = 5) or
tumor lysate + CpG + antagonist A26059 (n = 5) or tumor lysate + CpG +
control antagonist (n = 5). Mice were imaged weekly for tumor growth.
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